The out-of-pocket costs associated with treating obesity and secondary conditions, such as cardiovascular disease (CVD), can be prohibitive.1 When patients cannot afford these treatments, they often resort to cost-related prescription drug rationing.2 Glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer benefits in treating both obesity and CVD,3 but given their high prices,4 patients struggling with cost-related prescription rationing will be unable to access new therapies. This evidence concerns the gene GLP1R and Obesity.